Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...
Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...
Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...
MEDSIR, a leading international company in oncology research, has announced the results of the PHERGuide study during the 2025 San Antonio Breast Cancer Symposium (SABCS). This research, presented as ...
Daiichi Sankyo showcases strength of industry-leading ADC portfolio with latest research updates from five landmark breast cancer trials at SABCS: Tokyo Tuesday, December 9, 2025, ...
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, ...
Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in ...
Shanghai Junshi Biosciences Co., Ltd. Class H ( ($HK:1877) ) has issued an announcement. Shanghai Junshi Biosciences Co., Ltd. announced that the ...
The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% ...
DelveInsight’s “Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 250+ Breast Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback